Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026

The human papillomavirus (HPV) genotyping panels market size has grown steadily in recent years. It will grow from $1.79 billion in 2025 to $1.84 billion in 2026 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to the increasing incidence of HPV infections worldwide, growing awareness of cervical cancer screening initiatives, expansion of molecular diagnostic laboratory infrastructure, rise in government-supported screening programs, and increasing adoption of PCR-based diagnostic methods.

The human papillomavirus (HPV) genotyping panels market size is expected to see steady growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 3%. The growth in the forecast period can be attributed to increasing demand for personalized and precision diagnostics, rising adoption of next-generation sequencing technologies, expanding use of AI-enabled diagnostic interpretation systems, growing focus on early cancer detection and preventive healthcare, and increasing investment in advanced molecular diagnostic platforms. Major trends in the forecast period include rising adoption of next-generation sequencing-based HPV genotyping platforms, growing use of multiplex PCR assays for high-throughput viral detection, increasing demand for comprehensive cervical cancer screening solutions, expanding integration of digital pathology with molecular diagnostics, and growing shift toward automated and high-sensitivity diagnostic workflows.

The rising prevalence of HPV-related cancers is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. HPV-related cancers refer to malignancies caused by persistent infection with high-risk human papillomavirus strains, including cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, and penile cancer. The prevalence of HPV-related cancers is rising due to increasing rates of HPV infection globally and growing aging populations with higher cancer susceptibility. HPV genotyping panels support the management of rising HPV-related cancer prevalence by accurately identifying specific high-risk HPV strains, enabling early diagnosis, guiding targeted treatment decisions, and facilitating population-based cervical cancer screening programs. For instance, in 2025, according to the National Institutes of Health, a US-based government agency, globally, cervical cancer accounted for an estimated 662,044 new cases and 348,709 deaths in 2022, and these figures are projected to rise significantly, with cases increasing by 56.8% and deaths by 80.7% by 2050. Therefore, the rising prevalence of HPV-related cancers is driving the growth of the human papillomavirus (HPV) genotyping panels market.

The rising healthcare expenditure is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. Healthcare expenditure refers to the total spending on health services, including preventive care, diagnostic services, treatments, and healthcare infrastructure. The rise in healthcare expenditure is increasing due to expanding access to healthcare services and growing government investments in public health systems. HPV genotyping panels benefit from rising healthcare expenditure by enabling healthcare providers to invest in advanced molecular diagnostic tools, expand screening programs, improve laboratory infrastructure, and enhance early detection and management of HPV-related diseases. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the human papillomavirus (HPV) genotyping panels market.

Leading companies operating in the human papillomavirus (HPV) genotyping panels market are focusing on developing advanced solutions, such as self-collection-based diagnostic solutions to expand screening accessibility, improve early detection rates, and enhance patient compliance in cervical cancer prevention programs. Self-collection-based diagnostic solutions refer to testing approaches that allow patients to collect their own biological samples, which are then analyzed using molecular assays for accurate detection and genotyping of HPV infections. For example, in May 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, received FDA approval for its cobas HPV Self-Collection Solution, which is integrated with the cobas HPV test. The solution enables the detection of 14 high-risk HPV genotypes, including HPV 16 and HPV 18, and allows patients to self-collect samples within healthcare settings. This innovation improves access to screening, particularly for underserved populations, and supports broader adoption of HPV testing in routine clinical practice.

Major companies operating in the human papillomavirus (HPV) genotyping panels market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Hologic Inc., Revvity Inc., QIAGEN N.V., DiaSorin S.p.A., BGI Group, Seegene Inc., Fujirebio, Daan Gene Co. Ltd., Sansure Biotech Inc., Hybribio Limited, Tellgen Corporation, Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., 3B BlackBio Dx Limited, Jiangsu Macro & Micro-Test Med-Tech Co. Ltd., Mikrogen Diagnostik, GeneFirst Limited.

North America was the dominant region in the human papillomavirus (HPV) genotyping panels market in 2025. Asia-Pacific is expected to be the rapidly expanding regionin the forecast period. The regions covered in the human papillomavirus (HPV) genotyping panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human papillomavirus (HPV) genotyping panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) genotyping panels market consists of sales of partial genotyping panels, isothermal amplification HPV genotyping kits, line probe assay HPV genotyping kits, and lyophilized HPV genotyping kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The human papillomavirus (HPV) genotyping panels market research report is one of a series of new reports that provides human papillomavirus (HPV) genotyping panels market statistics, including human papillomavirus (HPV) genotyping panels industry global market size, regional shares, competitors with a human papillomavirus (HPV) genotyping panels market share, detailed human papillomavirus (HPV) genotyping panels market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) genotyping panels industry. This human papillomavirus (HPV) genotyping panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.